Batista G, Buvé A, Ngom Gueye N F, Manga N M, Diop M N, Ndiaye K, Thiam A, Ly F, Diallo A, Ndour C T, Seydi M
Service des maladies infectieuses, centre de traitement ambulatoire (CTA), centre hospitalier national universitaire (CHNU) de Fann à Dakar, BP 16760, Dakar Fann, Senegal.
Institute of Tropical Medicine, Nationalestraat 155, 2000 Antwerpen, Belgium.
Med Mal Infect. 2015 Jun;45(6):199-206. doi: 10.1016/j.medmal.2015.03.009. Epub 2015 Apr 20.
We determined the risk factors and incidence of clinical events associated with suboptimal immune reconstitution (SIR) defined by an increase in CD4 inferior to 50 cells/μL, from inclusion up to six months of antiretroviral treatment (ARVT), in patients with an undetectable viral load (<50 copies/mL).
Logistic regression and Cox's proportional hazards model were used to examine risk factors for SIR and the association between SIR and the risk of new clinical events or death, respectively after six months of ARVT.
One hundred and two (15.5%) of the 657 patients presented with SIR. Age > 40 years (aOR = 1.74, 95% CI = 1.10-2.75), baseline CD4 ≥ 100 cells/μL (aOR = 2.06, 95% CI = 1.24-3.42), ARVT including AZT (aOR = 4.57, 95% CI=1.06-19.76), and the occurrence of a severe opportunistic infection during the first semester of ARVT (aOR = 2.38 95% CI= 1.49-3.80) were associated with SIR. After six months of ARVT and up to seven years of follow-up, 39 patients with SIR had presented with an opportunistic infection or death (rate= 9.78/100 person-years) compared to 168 with a normal recovery (rate = 7.75/100 person-years) but the difference was not statistically significant (aHR = 1.22, 95% CI = 0.85 to 1.74).
SIR is less common in our country and is not associated with increased mortality or a greater incidence of opportunistic infections after six months of ARVT.
我们确定了病毒载量不可检测(<50拷贝/毫升)的患者中,与免疫重建不佳(SIR)相关的危险因素及临床事件发生率。SIR定义为从纳入研究至抗逆转录病毒治疗(ARVT)六个月期间,CD4细胞增加量低于50个/微升。
采用逻辑回归和Cox比例风险模型,分别研究SIR的危险因素以及ARVT六个月后SIR与新的临床事件或死亡风险之间的关联。
657例患者中有102例(15.5%)出现SIR。年龄>40岁(调整后比值比[aOR]=1.74,95%置信区间[CI]=1.10-2.75)、基线CD4≥100个/微升(aOR=2.06,95%CI=1.24-3.42)、包含齐多夫定(AZT)的ARVT方案(aOR=4.57,95%CI=1.06-19.76)以及ARVT第一学期出现严重机会性感染(aOR=2.38,95%CI=1.49-3.80)均与SIR相关。ARVT六个月后至七年随访期内,39例SIR患者出现机会性感染或死亡(发生率=9.78/100人年),而168例恢复正常的患者发生率为7.75/100人年,但差异无统计学意义(调整后风险比[aHR]=1.22,95%CI=0.85至1.74)。
SIR在我国不太常见,且与ARVT六个月后的死亡率增加或机会性感染发生率升高无关。